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Objective. In previous studies, cranial electrostimulation
(CES) had positive effects on sleep in depressed patients
and in patients with vascular dementia. The present
study examined the effects of low-frequency CES on the
rest-activity rhythm and cortisol levels of patients with
probable Alzheimer’s disease (AD). Method. It was
hypothesised that a decreased level of cortisol would par-
allel a positive effect of low-frequency CES on nocturnal
restlessness. Sixteen AD patients were randomly assigned
to an experimental group (n = 8) or a control group (n =
8). The experimental group was treated with CES, where-
as the control group received sham stimulation, for 30
minutes a day, during 6 weeks. The rest-activity rhythm
was assessed by actigraphy. Cortisol was measured
repeatedly in the saliva throughout the day by means of
salivette tubes. Results. Low-frequency CES did not
improve the rest-activity rhythm in AD patients. Moreover,
both groups showed an increase instead of a decrease in
the level of cortisol. Conclusions: These preliminary
results suggest that low-frequency CES has no positive
effect on the rest-activity rhythm in AD patients. An alter-
native research design with high-frequency CES in AD is
discussed.
Key Words: Cranial Electrostimulation—Alzheimer’s
disease—rest-activity rhythm—salivary cortisol.
Cranial electrostimulation (CES) is a noninva-sive type of intervention in which mild elec-trical stimulation is applied to the head.1 CES
is aimed at lowering anxiety and depression in var-
ious withdrawal conditions.1-7 The results of a
meta-analysis of randomized controlled trials indi-
cate that a reduction in anxiety appears to be the
most consistent effect of CES.8
The effects of CES on sleep have been examined
in only a few studies. Philip and coworkers3
observed stability in sleep duration in depressed
patients who were treated with CES, whereas a sig-
nificant shortening of the sleep period was found
in the placebo group. A sleep diary and a sleep
questionnaire assessed quality of sleep. To our
knowledge, CES was applied in only one study to
demented elderly, that is, elderly with a vascular
dementia.9 Behavioral disorders and disturbances
in sleep decreased after 2 weeks of treatment.
However, also the sleep quality in the control
group improved (sleep diary), possibly due to an
increased level of daytime vigilance caused by the
treatment-related interaction with the nurses.9
Hozumi et al.9 suggested that CES might partly be
mediated through the peripheral nervous system. A
type of electrostimulation that is completely medi-
ated by the peripheral nervous system is transcuta-
neous electrical nerve stimulation (TENS).
Interestingly, TENS significantly improved the rest-
activity rhythm in patients in both early and more
advanced stages of Alzheimer’s disease (AD).10,11
The improvement in rest-activity rhythm indicated
a stronger coupling between the rest-activity
rhythm and supposedly stable Zeitgebers. In addi-
tion, nocturnal restlessness in the AD patients
decreased. These findings suggest that TENS may
stimulate the hypothalamic suprachiasmatic nucle-
us (SCN), the biological clock of the brain that is
related to disturbances in circadian rest-activity
rhythms in AD.12,13
Further support for a mutual mechanism under-
lying CES and TENS emerges from studies on the
effects of both types of electrostimulation on vari-
ous neurotransmitters. TENS might activate, for
example, the hypothalamus through direct spino-
hypothalamic pathways14 but also indirectly
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through the locus coeruleus (LC) and dorsal raphe
nucleus (DRN).15,16 These two brain stem areas—
both affected in AD17—are the origin of the ascend-
ing noradrenergic and serotonergic neurotransmit-
ter systems, respectively.18,19 Therefore, both brain
stem areas are “target” areas in our electrical stim-
ulation studies. Interestingly, increased levels of
noradrenaline and serotonin have also been
observed after transcranial electrostimulation thera-
py in rats.20 Transcranial electrostimulation therapy
is synonymous with CES.
Although the neurons of the LC/noradrenergic
system and the DRN/serotonergic system are capa-
ble of reacting to both low and high frequency
stimulation,21-24 it is noteworthy that different stim-
ulation frequencies have a different effect on both
systems. Low-frequency stimulation of, for exam-
ple, 0.1 or 4 Hz preferably appeals to the LC/nor-
adrenergic system, compared to the DRN/seroton-
ergic system.23 The neurons of the DRN/serotoner-
gic system are most responsive to high frequency
stimuli of, for example, 10, 20, and 100 Hz.23,25-27
Improvement in the rest-activity rhythm by acti-
vating the hypothalamus was the main goal of the
present study. There are strong projections
between the LC and the hypothalamus/SCN,16 and
results of various recent studies suggest that,
through the LC/noradrenergic system, low-frequency
electrical stimulation activates the hypothala-
mus.23,28,29 Therefore, it was hypothesized in the
present study that low-frequency CES could
decrease disturbance in the sleep-wake rhythm in
patients in a relatively early stage of AD.
The extent of sleeplessness might be reflected in
the level of cortisol.30-32 An increased level of corti-
sol, indicative of a hyperactive hypothalamic-pitu-
itary-adrenal axis, was found to coincide with sleep
disturbance. Therefore, the second hypothesis of
the present study implied that an improvement in
the rest-activity rhythm by CES would be reflected
in a decrease in the level of cortisol.
METHOD
Participants
The local ethics committee gave approval for the
study. The sample consisted of 16 participants and
was drawn randomly from a larger sample of 500
elderly persons who lived in a residential home.
The participants gave their informed consent to
undergo a first global screening.
All participants met the NINCDS-ADRDA criteria
for the clinical diagnosis of probable AD.33 The
clinical symptoms of dementia had been present
for at least 6 months. Subjects were excluded from
participation in this study if they had a history of
psychiatric disorder, alcoholism, cerebral trauma,
cerebrovascular disease, hydrocephalus, neoplasm,
epilepsy, disturbances of consciousness, or focal
brain disorders. None of the participants had a
pacemaker. All patients met the criteria for early
AD, that is, stage 5 of the Global Deterioration
Scale.34 Level of cognitive functioning was assessed
by the 20-item version of the Mini-Mental State
Examination (MMSE), with a maximum score of
30.35 The level of education was quantified on a 5-
point Likert-type scale: elementary school not fin-
ished = 1, elementary school finished = 2, lower
secondary school = 3, higher secondary school = 4,
higher vocational training for 18+/university = 5.
The 16 participants were randomly assigned to
an experimental group (n = 8: 2 males, 6 females)
or a control group (n = 8: 1 male, 7 females). The
mean age of the participants of the experimental
group (M = 86.75) did not differ significantly from
the mean age of the control group (M = 87.88),
t(14) = 0.38, ns. The mean MMSE score of the
experimental group (M = 17.88) was not signifi-
cantly different from the mean MMSE of the control
group (M = 20.38) (Mann-Whitney U: z = 1.37, ns).
There was no significant difference between the
level of education of the experimental group (M =
3.25) and the control group (M = 3.00) (Mann-
Whitney U: z = 0.26, ns).
Following the first global screening, the partici-
pants and their families were extensively informed
about the aim and procedure of the investigation
and gave their informed consent to continue the
screening procedure. Before onset of the treatment
procedure, a trial treatment was applied to both the
experimental and the control group. No negative
reactions of the participants were observed. The
participants and their relatives were not aware of
the group in which they participated, thus prevent-
ing a possible bias.
Material and Procedure
ASSESSMENT OF THE 
CIRCADIAN RHYTHMS
The rest-activity rhythm. The circadian rest-activity
rhythm was assessed noninvasively by an actigraph
Scherder et al.
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(Actiwatch, Cambridge Neurotechnology, Cam-
bridge, UK). The actigraph has the size and shape
of a watch, is worn on the dominant wrist, and reg-
isters acceleration-induced wrist movements. The
actigraph quantifies accelerations due to motor
activity of the arm and integrates these over 1-
minute periods. The participants were asked to
wear the actigraph 24 hours a day for 1 week. From
the resulting rest-activity rhythms, 3 nonparametric
variables were calculated36 using the Actiwatch
Sleep Analysis 2001 software (Cambridge
Neurotechnology, Cambridge, UK). First, the inter-
daily stability (IS) variable that quantifies the
strength of coupling between the rest-activity
rhythm and supposedly stable Zeitgebers (e.g.,
meals) was calculated. The second variable was the
intradaily variability (IV), which quantifies the frag-
mentation of the rhythm, that is, the frequency and
extent of transitions between rest and activity. The
third variable was the relative amplitude (RA). The
RA quantifies the difference between the main
activity (day) and rest (night) periods.
Salivary cortisol measurement. There is ample evi-
dence that salivary cortisol is a reliable reflection of
cortisol concentrations in blood.37,38 It represents
cortisol that is not bound to plasma proteins and,
therefore, reflects the biologically active free hor-
mone concentration. Salivary cortisol samples were
obtained by means of salivette tubes (Sarstedt,
Rommelsdorf, Germany). The participants were
asked to chew on a cotton-wool swab for about 1
minute, which is sufficient to collect enough mate-
rial for analyses.38 Sampling took place at 9 differ-
ent points during 24 hours. Sampling started imme-
diately after the moment of awakening (measure-
ment 1), which was different for each person. One
and 2 hours later, the 2nd and 3rd measurement
took place. The 4th sample was at noon, followed
by a 5th sample at 2:00 PM. The 6th sample was
scheduled 3 hours before the expected time to
sleep (which was different for each participant),
the 7th sample 2 hours before that moment, fol-
lowed by an 8th sample 1 hour before sleep onset.
The final 9th measurement was acquired just
before the participant went to sleep. All saliva sam-
pling was conducted between 7:30 AM and 9:30
PM. In view of the individual variation in awaken-
ing and sleep onset, it should be noted that only 2
occasions of measurement were the same for each
participant, that is, at noon and at 2:00 PM. We
decided not to collect saliva during the night
because awakening was expected to interfere with
cortisol level and rhythms. After sampling, the sali-
va was stored at –20 oC. Because the duration of
the study was 1.5 years and the participants were
randomly assigned to both groups in parallel, sea-
son effects can be disregarded.
Cortisol analysis. Salivary cortisol was measured by
a coated tube radioimmunoassay with the Orion
Diagnostica SPECTRIA Cortisol Ria Test (Orion
Corporation Orion Diagnostica, Espoo, Finland).
PROCEDURE
Treatment. CES was applied by the AlphaStim 100,
which generates bipolar asymmetric rectangular
waves, with a frequency of 0.5 Hz39 and an inten-
sity between 10 and 600 µA. The electrodes were
clipped on to the earlobes. The investigator adjust-
ed the current until the patient indicated feeling a
tingling sensation and/or dizziness and then
reduced the current to just below the reported
threshold of sensation. If the patient experienced no
sensation, the current was increased to a maximum
level (600 µA). The experimental group was admin-
istered stimulation time for 30 minutes each day.
Participants were treated for a period of 6 weeks, 5
days a week between 15.00 and 19.00 hours.
Participants in the control group were treated in the
same way as the experimental group, only no cur-
rent was administered. The interpersonal commu-
nication during the treatment was identical for both
the control and the experimental groups.
Moments of measurement. The actigraphy and cor-
tisol measurements took place before the 6-weeks
treatment period with (sham) CES (pre), after the 6-
weeks treatment period (post), and again after a
treatment-free period of 6 weeks (delayed).
Statistical Analyses
Actigraphy. Actigraphic variables were analyzed by
multivariate analyses of variance (MANOVA) with
group (treatment and control group) as an inde-
pendent factor and time (3 levels—pretreatment:
T1, posttreatment: T2, and after a treatment-free
period: delayed: T3) as a repeated measurements
factor. Even when no significant interactions
between group and time were found, the explo-
rative character of this pilot study justified that the
data were submitted to 1 degree of freedom inter-
action F statistics. When interactions between
group and time occurred concerning T1 and T2, T2
Cranial Electrostimulation in Alzheimer’s Disease
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and T3, and T1 and T3, paired within-group t tests
would be performed. This appeared not to be the
case in the present study (see the Results section).
Effect sizes (eta squared [η2]) were calculated, that
is, small < .01, medium < .06, and large ≥ .14.
The Bonferroni correction was applied to the
significance level of P < 0.05, resulting in a critical
value of P < 0.01. The SPSS-PC program40 was used
to analyze the data.
Cortisol measurements. The (at most) 27 cortisol
measures per person were obtained at irregular
times between 8:00 AM and 10:00 PM, which
makes a repeated measures analysis of variance
inapplicable. Instead, a multilevel analysis41 is more
appropriate.
Multilevel modeling is a general technique for
the analysis of clustered or correlated data, for
example, pupils within schools, children within
families, and repeated observations within a per-
son. In general, the level-1 units (pupils or chil-
dren) are to be differentiated from the level-2 units
(schools or families). Although perhaps less obvi-
ous, in the context of repeated measurements the
level-2 units represent the persons and the level-1
units the measurements. Standard repeated meas-
ures ANOVA and MANOVA are both special cases
of the multilevel model. An advantage of the mul-
tilevel modeling is that missing data can be dealt
with in a rather easy way (in our data set, we have
387 measurements from the maximum of 27 [9
samples at pre, post, and delayed measurement ×
16 [2 groups × 8 participants in each group] = 432).
A second advantage of multilevel modeling is that
we can model the daily (24-h) cyclical pattern of
the cortisol measures.42
It is well known that any periodic function can
be fitted by a Fourier series, that is, a sum of sine
and cosine waves.43 To fit our data, 2 harmonics
were needed, with period 24 h and 12 h, respec-
tively. The effects of CES and time were modeled
in the usual way by incorporating dummy variables
for group (CES vs. placebo), time (post vs. pre and
del (delay) vs. pre), and the Group × Time interac-
tion to the model. The fixed part of the model can
be symbolically written as
Cortisol = Intercept + Group + Time + Group × Time
+ Sin       + Cos       + Sin       + Cos ,
where t is the time in hours between 0 and 24 at
which the measurement takes place.
To allow for variability between persons, a ran-
dom model for the level-2 units has to be defined.
Usually, some terms of the fixed part of the model
are needed as random level-2 terms. For our data,
random intercept terms and the sine and cosine
terms of the first harmonic were needed. Finally, a
random measurement term (represented by the
level-1 intercept term) was added to complete the
model.
Considering the paucity in studies in this field
and conflicting results of some of the studies, two-
tailed tests were used here. Multilevel analysis was
performed with the MLwiN (version 1.10) software
package.44
RESULTS
Effects of CES on the 
Rest-Activity Rhythm
Means and standard deviations are presented in
Table 1. Repeated measures MANOVA did not
reveal significant Group × Time interaction effects
for IS, F(2, 11) = 0.12, P = 0.89; IV, F(2, 11) = 1.79,
P = 0.21; and RA, F(2, 11) = 0.56, P = .59. One
degree of freedom interaction F statistics did not
show any significant difference between both
groups after the treatment period (T1-T2).
Effects of CES on Salivary Cortisol
The fitted multilevel model (see Data Analyses in
the Method section) for the mean curves is shown
Scherder et al.
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Table 1. Means, Standard Deviations, and Analyses of Variance of the Various Scales and Actigraphy
Experimental Group Control Group
ANOVA Effect
Pre Post Del Pre Post Del Pre-Post Size
Actigraphy M SD M SD M SD M SD M SD M SD F(1, 14) P η2
IS .53 .10 .56 .08 .53 .20 .43 .20 .48 .19 .47 .19 .03 0.87 .01
IV 1.32 .25 1.40 .28 1.55 .33 1.31 .38 1.47 .38 1.43 .44 .34 0.57 .03
RA .83 .11 .79 .11 .71 .14 .63 .23 .59 .20 .59 .21 .04 0.86 .01









 at Vrije Universiteit 34820 on November 29, 2010nnr.sagepub.comDownloaded from 
in Figure 1, and the parameter estimates are
given in Table 2 (interaction model). From
these estimates, the 6 Group × Time mean
curves are computed, evaluated at value 0
for the periodic function (see Table 3). As
can be seen in Figure 1, the minimum cor-
tisol level occurred at about 6:00 PM,
whereas the projected maximum level (not
shown in Figure 1) was reached at about
3:00 AM. The amplitude of the rhythm, that
is, the difference between the minimum and
the maximum, was 21.20 nmol/l. However,
the results on amplitude and peak time
should be considered with caution because
the maximum cortisol level has been
obtained by extrapolation from the fitted
curves.
Data analyses further showed that there
was no significant interaction effect
between group and time, including Group × Post
(T2) and Group × Del (T3) (likelihood ratio chi-
squared = 3.70, df = 2, P = 0.16). The mean corti-
sol values as presented in Tables 2 and 3 clearly
indicate that in both groups, the change in cortisol
levels was in the unpredicted direction; that is, after
CES (at T2) the cortisol level was increased, where-
as we hypothesized a decrease in the experimental
group only. Because the Group × Time interaction
was not significant, the model was also fitted with-
out interaction. The parameter estimates are shown
in Table 2 (no interaction model). We tested in this
model the main effects of time: likelihood ratio chi-
squared = 20.47, df = 2, P < 0.0001 (post vs. pre: z
= 2.75, P = 0.006; del vs. pre: z = 4.57, P < .0001).
DISCUSSION
The results suggest that low-frequency CES has no
beneficial influence on the rest-activity rhythm and
cortisol levels in AD patients. The mean scores on
the actigraphy variables IS, IV, and RA hardly
changed (Table 1). Furthermore, after both CES
treatment and after placebo, cortisol levels were
significantly increased (Table 2, Table 3, Figure 1).
The level of cortisol further increased during the
period without treatment.
In the present study, the lowest cortisol level
occurred at 6:00 PM (Figure 1), not an unusual
finding in AD.45 However, in AD the cortisol level
has been reported to remain at this level until mid-
night,45 whereas in our patient group the cortisol
level increased directly after 6:00 PM (Figure 1).
Our patients were institutionalized, and after 6:00
PM the preparations for the night are already start-
ing. For the residents, this is often a stressful event,
possibly causing an increased cortisol response.46
The question arises whether a conclusion about
the ineffectiveness of low-frequency CES in AD is
appropriate, considering the small number of par-
ticipants. However, a comparable number of par-
ticipants were included in previous studies that did
report beneficial effects of CES47 and TENS10,11 on
the rest-activity rhythm. Because CES has never been
applied to AD patients, effect sizes and, consequent-
ly, the number of participants could not be estimat-
ed before the start of the present study. In our
opinion, by examining a new type of intervention
that is very time-consuming and therefore costly, it
is most important to perform a study of feasible
sample size, calculate effect sizes, and evaluate the
direction of the change in scores. The data show
that in this group of patients, clinically relevant
effects will not be obtained with this CES proce-
dure. Therefore, in our opinion it is justified to dis-
continue the investigation of low-frequency CES as a
treatment for circadian rhythm disturbances in AD.
Another important question is why low frequen-
cy CES was ineffective in AD. In 2 animal experi-
mental studies and 1 human fMRI study with
healthy participants, the activation of the hypothal-
amus was enhanced by low-frequency electro-
acupuncture and mediated by the LC/noradrener-
gic system.23,28,29 However, in the present study,
low-frequency CES was applied to AD patients
with an extensive neuropathology, affecting more
than 1 neurotransmitter system, for example, the
serotonergic and the noradrenergic system.48 One
could argue that to obtain a more effective activa-
tion of the hypothalamus in AD, the LC/noradren-
ergic and DRN/serotonergic system might have to
Cranial Electrostimulation in Alzheimer’s Disease




























Figure 1. The fitted multilevel model for the mean values of saliva
cortisol (nmol/l) of the experimental and control group between 8:00
AM and 10:00 PM. Pre = pretreatment; post = posttreatment, del =
delayed (after treatment-free period); CES = cranial electrostimulation.
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be stimulated simultaneously to mimic neurophys-
iology as much as possible. Results from animal
experimental studies indicate that the influence of
the DRN/serotonergic system on the LC/noradren-
ergic system, which contains serotonin perikarya, is
essential for the function of the latter system.49 For
example, the serotonergic system might exert an
excitatory influence on the noradrenergic system,
resulting in an increased release of serotonin in the
LC26 and a subsequent increased release of nora-
drenaline in the hypothalamus.50 These latter find-
ings imply that for an optimal functioning of the
LC, the interaction between DRN and LC is a pre-
requisite.49 Consequently, not only stimulation of
the LC/noradrenergic system but also of the
DRN/serotonergic system should be included in the
treatment. In the TENS studies, in which the circa-
dian rest-activity rhythm of AD patients
improved,10,11 the selective sensitivity of the sero-
tonergic and noradrenergic neurotransmitter sys-
tems for high- and low-frequency stimulation,
respectively, could be met by using the BURST-
TENS mode.51 In the BURST-TENS mode, high- and
low-frequency stimulation are combined in 1 treat-
ment; that is, a frequency of 160 Hz is applied to
the patients in 2 bursts per second (2 Hz), that is,
2 blocks of trains of impulses.
In contrast to BURST-TENS, CES can be applied
only in a low- or high-frequency mode: 0.5 and 100
Hz, respectively. As noted in the introduction, the
neurons of the DRN/serotonergic system preferably
respond to high frequency stimulation, for exam-
ple, 10 and 100 Hz.26,27 It should be noted, howev-
er, that the LC/noradrenergic neurons are well able
Scherder et al.
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Table 2. Parameter Estimates and Standard Errors (SE) of the Multilevel Two-Harmonics Models to Fit the Cortisol Level
in the Experimental Group and the Control Group, at Baseline (pre), after a 6-Week Treatment Period (post), and after
a 6-Week Treatment-Free Period (del)
Interaction Model No Interaction Model
Fixed Effects Parameter Estimate SE Parameter Estimate SE
Intercept 12.56 1.68 12.19 1.65
Group (treatment versus control) –0.71 1.20 –0.001 1.01
Time
Post (vs. pre) 1.44 0.83 1.63 0.59
Del (vs. pre) 1.84 0.83 2.81 0.61
Group × Time
Group × Post 0.34 1.17
Group × Del 2.22 1.23
Sin 7.88 1.33 7.90 1.34
Cos 6.23 1.77 6.28 1.77
Sin 2.90 0.88 2.90 0.88
Cos 0.44 0.49 0.48 0.49
Random Effects Variance Component SE Variance Component SE
Level 2
Var(intercept) 22.83 8.88 22.93 8.92
Var(sin       ) 11.94 5.53 12.00 5.56
Var(cos       ) 27.27 11.32 27.23 11.32
Cov(intercept, sin       ) 15.94 6.66 16.02 6.92
Cov(intercept, cos ) 22.67 9.45 22.53 9.44
Cov(sin       , cos       ) 16.83 7.44 16.86 7.46
Level 1
Var(intercept) 22.15 1.70 22.35 1.72
–2 log likelihood 2348.64 2352.34
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to react to high-frequency stimulation of, for exam-
ple, 100 Hz.23 Support for high-frequency CES as a
possible more effective treatment strategy in AD
emerges from studies with transcranial magnetic
stimulation (TCMS). Kimbrell and coworkers52
observed that the effectiveness of TCMS on depres-
sion appeared to be dependent on the level of
baseline glucose metabolism. A frequency of 20 Hz
showed a higher antidepressant effect in patients
with a baseline cerebral glucose hypometabolism,
whereas a frequency of 1 Hz was most effective in
patients with a baseline cerebral glucose hyper-
metabolism. It is known that the global level of
brain glucose metabolism shows a significant decre-
ment in AD compared to nondemented elderly per-
sons.53 These authors argued that in AD, neuro-
pathological changes such as atrophy lower the
brain metabolism. Conversely, a low glucose meta-
bolism is found to increase the risk for dementia.54
In sum, the results of studies that indicate that
both the DRN/serotonergic system as well as the LC/
noradrenergic system are able to respond to high-
frequency stimulation, together with the effective-
ness of high-frequency TCMS in patients with cere-
bral glucose hypometabolism, justify a next study on
the hypothesis that, instead of low-frequency CES,
high-frequency CES improves the rest-activity rhythm
in AD patients.
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